Back to top
Clinical stage:
In vitro

Aprepitant is an anti-emetic drug used in oncology. N4 Pharma is seeking to improve the speed at which the drug takes effect whilst also extending its duration of action in a manner similar to its reformulated Sildenafil.

This anti-emetic, which operates in the post-surgery and cancer markets had global annual sales of approximately $549 million* in 2016.

*Source: Evaluate Pharma